Beclomethasone nasal spray doesn't increase IOP in patients with ocular hypertension and primary open-angle glaucoma, reveals a study in the Journal of Glaucoma.
Beclomethasone nasal spray doesn't increase IOP in patients with ocular hypertension and primary open-angle glaucoma, reveals a study in the Journal of Glaucoma.
Dr D. Yuen et al., Department of Ophthalmology and Visual Sciences, Toronto Western Hospital, Toronto, Canada, completed a randomized, double-masked, controlled trial on 19 patients who were randomized to twice-daily beclomethasone versus placebo saline nasal spray.
Four study visits were conducted: baseline, a weeks 2, 4, 6 after starting the nasal spray. The primary outcome measure was IOP and secondary measures were visual acuity, anterior segment changes, patient reported side effects and compliance.
There were no statistically significant differences in baseline characteristics, IOP at each study visit, or change in IOP between the two groups. The mean change in IOP from baseline was +0.50±1.52 versus +0.70±1.44 mm Hg in the steroid and saline nasal spray groups, respectively at the six-week follow-up, concluding that beclomethasone nasal spray does not affect IOP in OHT and POAG patients.
To view the abstract please click here.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.